144 related articles for article (PubMed ID: 38307787)
1. Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review.
Parikh S; Zhang Y; Sherwani Z; Kumar R; Ohri N; Jan I; Vergalasova I; Jabbour S; Hathout L
Brachytherapy; 2024; 23(2):141-148. PubMed ID: 38307787
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy.
Roach E; Hutten R; Johnson S; Suneja G; Tward J; Petereit D; Gaffney D
Brachytherapy; 2024; 23(3):360-367. PubMed ID: 38395662
[TBL] [Abstract][Full Text] [Related]
4. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of hypofractionation for primary management of prostate cancer.
Koontz BF; Bossi A; Cozzarini C; Wiegel T; D'Amico A
Eur Urol; 2015 Oct; 68(4):683-91. PubMed ID: 25171903
[TBL] [Abstract][Full Text] [Related]
6. Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(27):1-118. PubMed ID: 23074405
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.
Williams VM; Kahn JM; Harkenrider MM; Chino J; Chen J; Fang LC; Dunn EF; Fields E; Mayadev JS; Rengan R; Petereit D; Dyer BA
Brachytherapy; 2020; 19(4):401-411. PubMed ID: 32359937
[TBL] [Abstract][Full Text] [Related]
8. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
9. Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic.
Damast S; Tien CJ; Young M; Altwerger G; Ratner E
J Contemp Brachytherapy; 2022 Feb; 14(1):66-71. PubMed ID: 35233237
[TBL] [Abstract][Full Text] [Related]
10. Early outcomes of abbreviated multi-fractionated brachytherapy schedule for cervix cancer during COVID-19 pandemic.
Chopra S; Mulani J; Mittal P; Singh M; Shinde A; Gurram L; Scaria L; Aravindakshan D; Kohle S; Rane P; Ghadi Y; Rath S; Ghosh J; Gulia S; Gupta S; Kinhikar R; Laskar S; Agarwal JP
Brachytherapy; 2023; 22(2):125-131. PubMed ID: 36585283
[TBL] [Abstract][Full Text] [Related]
11. The Impact of COVID-19 on Brachytherapy During the Pandemic: A Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience.
Hathout L; Ennis RD; Mattes MD; Wagman RT; Grann A; Jabbour SK; Singh R; Yue NJ; Haffty BG; Vergalasova I
Adv Radiat Oncol; 2021; 6(1):100600. PubMed ID: 33163697
[TBL] [Abstract][Full Text] [Related]
12. An umbrella review of systematic reviews on the impact of the COVID-19 pandemic on cancer prevention and management, and patient needs.
Muka T; Li JJX; Farahani SJ; Ioannidis JPA
Elife; 2023 Apr; 12():. PubMed ID: 37014058
[TBL] [Abstract][Full Text] [Related]
13. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials.
Tabrizi S; Trippa L; Cagney D; Aizer AA; Tanguturi S; Ventz S; Fell G; Bellon JR; Mamon H; Nguyen PL; D'Amico AV; Haas-Kogan D; Alexander BM; Rahman R
JAMA Netw Open; 2021 Mar; 4(3):e213304. PubMed ID: 33779742
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review.
Mostafavi Zadeh SM; Tajik F; Gheytanchi E; Kiani J; Ghods R; Madjd Z
BMJ Support Palliat Care; 2023 Sep; ():. PubMed ID: 37748857
[TBL] [Abstract][Full Text] [Related]
16. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE
Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional-guided perineal-based interstitial brachytherapy in cervical cancer: A systematic review of technique, local control and toxicities.
Mendez LC; Weiss Y; D'Souza D; Ravi A; Barbera L; Leung E
Radiother Oncol; 2017 May; 123(2):312-318. PubMed ID: 28351521
[TBL] [Abstract][Full Text] [Related]
18. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer.
Contreras J; Srivastava A; Chundury A; Schwarz JK; Markovina S; Thaker PH; Massad LS; Mutch DG; Powell MA; Grigsby PW; Lin AJ
Int J Gynecol Cancer; 2020 Aug; 30(8):1157-1161. PubMed ID: 32527770
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]